LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net salesSAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast A ...